Ginkgo bioworks signs definitive agreement to acquire fgen ag, a leading bioengineering company and its proprietary ultra-high-throughput screening platform

Boston and basel, switzerland , march 14, 2022 /prnewswire/ -- ginkgo bioworks (nyse: dna), the leading horizontal platform for cell programming, today announced the entry into a definitive agreement to acquire fgen ag ("fgen"), a swiss company specializing in strain development and optimization. fgen has developed an ultra-high-throughput (uht) screening platform built on nanoliter reactor technology.
DNA Ratings Summary
DNA Quant Ranking